Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Erlotinib (Primary) ; Carboplatin; Docetaxel
- Indications Adenocarcinoma; Breast cancer
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 18 Jan 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
- 31 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History